DATAPHARM Powers Medicinal Cannabis Education Initiative
Launched this week, New Zealand's medicinal cannabis information service is focused on delivering quality prescriber education programmes and resources to support patients across the country.
New Zealand’s largest licenced medicinal cannabis company, Helius Therapeutics, has announced an exclusive partnership with DATAPHARM, focused on delivering leading prescriber education programmes and resources.
New Zealand-owned DATAPHARM is well known for consulting to the healthcare and pharmaceutical industries and creating innovative product services. The new information service – MCinfo.com – launched at this week's GP CME in Rotorua. MCinfo.com is supported by Helius Therapeutics as Education Sponsor.
DATAPHARM will deliver in-person programmes nationwide and an online platform boasting the most definitive medicinal cannabinoid information available in New Zealand.
“We know enhancing prescriber knowledge is key to ensuring greater patient access to medicinal cannabis. Helius is steadfastly committed to education and so we’re thrilled to once again be collaborating with the best in the business,” says Carmen Doran, Chief Executive of Helius Therapeutics.
Medicinal cannabinoids can now be prescribed by every GP in New Zealand, for any condition. Yet, according to a Horizon Research survey, 76% of healthcare professionals have reported a need to be better informed about cannabinoid medicines and how to prescribe relevant products.
As well as Helius’ sponsorship enabling highly-trained representatives on the road to better inform healthcare professionals about medicinal cannabis, registrations to the newly-built MCinfo.com will be strongly encouraged.